Grupo mixto de investigación y traslación de cáncer de próstata

Larrinaga G, Redrado M, Loizaga Iriarte A, Perez Fernandez A, Santos Martin A, Angulo JC, et al. Spatial expression of fibroblast activation protein-a in clear cell renal cell carcinomas revealed by multiplex immunoprofiling analysis of the tumor microenvironment. Cancer Immunol Immunother. 2025; 74(2). DOI:10.1007/s00262-024-03896-y.

Schaub Clerigue A, Hermanova I, Pintor Rial A, Sydorenko M, Valcarcel Jimenez L, Macchia A, et al. Secreted spermidine synthase reveals a paracrine role for PGC1a-induced growth suppression in prostate cancer. Cell Death Dis. 2025; 16(1): 330-330. DOI:10.1038/s41419-025-07639-4.

Lee SY, Prieto Fernandez E, Egia Mendikute L, Antonaña Vildosola A, Velasco Beltran P, Bosch A, et al. Syndecan-3 positively regulates the pro-inflammatory function of macrophages. Cell Mol Life Sci. 2025; 82(1). DOI:10.1007/s00018-025-05649-1.

Martin N, Garcia Longarte S, Corres Mendizabal J, Lazcano U, Astobiza I, Bozal Basterra L, et al. Transcriptional analysis of metastatic hormone-naïve prostate cancer primary tumor biopsies reveals a relevant role for SOX11 in prostate cancer cell dissemination. Genome Biol. 2025; 26(1): 154-154. DOI:10.1186/s13059-025-03623-5.

Bozal Basterra L, Salazar M, Ferreira Campos AM, Demicco M, Schmidt DR, Sobczak K, et al. Loss of UFMylation supports prostate cancer metastasis and rewires cell metabolism towards hexosamine biosynthesis. Biorxiv : The Preprint Server For Biology. 2025. DOI:10.1101/2025.06.02.657324.

Castellnou P, Gomez Martinez M, Gomez Vallejo V, Baz Z, Lopez Gallego F, Rondon Lorefice I, et al. Unravelling the role of L- and D- alanine in prostate cancer: a Positron Emission Tomography study in a genetic mouse model. Nuclear Medicine And Biology. 2025; 148-149: 109048-109048. DOI:10.1016/j.nucmedbio.2025.109048.

Crespo JR, Martin N, Garcia Longarte S, Corres Mendizabal J, Carlevaris O, Astobiza I, et al. The PP2A regulator IER5L supports prostate cancer progression (vol 15, 514, 2024). Cell Death Dis. 2025; 16(1). DOI:10.1038/s41419-025-07802-x.

Mercado Gomez M, Goikoetxea Usandizaga N, Gine AE, Rodrigo M, Afonso MB, Azkargorta M, et al. Role of CNNM4 in the progression of cholangiocarcinoma: implications for ferroptosis and therapeutic potential. Gut. 2025. DOI:10.1136/gutjnl-2024-333255.

Larrinaga G, Valdivia A, Arrieta Aguirre I, Solano Iturri JD, Ugalde Olano A, Loizaga Iriarte A, et al. The Expression of Alamandine Receptor MrgD in Clear Cell Renal Cell Carcinoma Is Associated with a Worse Prognosis and Unfavorable Response to Antiangiogenic Therapy. Int J Mol Sci. 2024; 25(3). DOI:10.3390/ijms25031499.

Unda M, Cozar Olmo JM, Alvarez Osorio JL. Why is it necessary to produce a BCG strain in Spain?. Actas Urol Esp (Engl Ed). 2024; 48(7): 487-489. DOI:10.1016/j.acuroe.2024.04.003.

Gil Redondo R, Conde R, Bruzzone C, Seco ML, Bizkarguenaga M, González Valle B, et al. MetSCORE: a molecular metric to evaluate the risk of metabolic syndrome based on serum NMR metabolomics. Cardiovasc Diabetol. 2024; 23(1). DOI:10.1186/s12933-024-02363-3.

Rodriguez Faba O, Fernandez Gomez JM, Guerrero Ramos F, Alvarez Maestro M, Ledo Cepero MJ, Unda Urzaiz M, et al. Consensus document on the implications of standardization of BCG supply in the management of patients with non-muscle-invasive bladder cancer. Actas Urol Esp (Engl Ed). 2024; 48(10): 718-731. DOI:10.1016/j.acuroe.2024.09.005.

Borque Fernando A, Perez Fentes DA, Rodrigo Aliaga M, Puente Vazquez J, Gomez Iturriaga A, Unda M, et al. Optimizing triple therapy in patients with metastatic hormone-sensitive prostate cancer. Actas Urol Esp (Engl Ed). 2024. DOI:10.1016/j.acuroe.2024.10.005.

Álvarez Ossorio JL, Rodrigo Aliaga M, Rodríguez Antolin A, Unda Urzaiz M, Calleja MÁ, de la Cruz Ruiz M, et al. Hormone sensitive protocol for metastatic prostate cancer, an update. Actas Urol Esp (Engl Ed). 2023; 47(4): 244-249. DOI: 10.1016/j.acuroe.2022.10.002.

Loizaga Iriarte A, Lacasa Viscasillas I, Rey Gonzalez S, Santos Martin A, Gonzalo Aparicio D, Ugalde Olano A, et al. Identifying prognostic parameters related to surgical technique in patients treated by robotic radical prostatectomy. Actas Urol Esp (Engl Ed). 2023; 47(1): 47-55. DOI: 10.1016/j.acuroe.2022.07.001.

Angulo JC, Álvarez-Ossorio JL, Domínguez-Escrig JL, Moyano JL, Sousa A, Fernández JM, et al. Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial. Eur Urol Oncol. 2023; 6(1): 58-66. DOI: 10.1016/j.euo.2022.10.008.

Martín-Saiz L, Abad-García B, Solano-Iturri JD, Mosteiro L, Martín-Allende J, Rueda Y, et al. Using the Synergy between HPLC-MS and MALDI-MS Imaging to Explore the Lipidomics of Clear Cell Renal Cell Carcinoma. Anal Chem. 2023; 95(4): 2285-2293. DOI: 10.1021/acs.analchem.2c03953.

Borque-Fernando A, Calleja-Hernández MA, Cózar-Olmo JM, Gómez-Iturriaga A, Pérez-Fentes DA, Puente-Vázquez J, et al. A multidisciplinary consensus statement on the optimal pharmacological treatment for metastatic hormone-sensitive prostate cancer. Actas Urol Esp (Engl Ed). 2023; 47(2): 111-126. DOI: 10.1016/j.acuroe.2022.12.004.

Borque-Fernando A, Calleja-Hernández MA, Cózar-Olmo JM, Gómez-Iturriaga A, Pérez-Fentes DA, Puente-Vázquez J, et al. Abiraterone in low-volume metastatic hormone-sensitive prostate cancer. Authors' reply. Actas Urol Esp (Engl Ed). 2023; 47(6): 392-393. DOI: 10.1016/j.acuroe.2023.04.014.

García-Vílchez R, Añazco-Guenkova AM, Dietmann S, López J, Morón-Calvente V, D'Ambrosi S, et al. METTL1 promotes tumorigenesis through tRNA-derived fragment biogenesis in prostate cancer. Mol Cancer. 2023; 22(1): 119. DOI: 10.1186/s12943-023-01809-8.

Carracedo A. Metabolism in the tumor cell and beyond. Mol Oncol. 2023; 17(6): 921-924. DOI: 10.1002/1878-0261.13467.

Plou J, Valera PS, García I, Vila-Liarte D, Renero-Lecuna C, Ruiz-Cabello J, Carracedo A, Liz-Marzán LM. Machine Learning-Assisted High-Throughput SERS Classification of Cell Secretomes. Small. 2023 12:e2207658. DOI: 10.1002/smll.202207658.

Santasusagna S, Zhu S, Jawalagatti V, Carceles-Cordon M, Ertel A, Garcia-Longarte S, et al. Master Transcription Factor Reprogramming Unleashes Selective Translation Promoting Castration Resistance and Immune Evasion in Lethal Prostate Cancer. Cancer Discov. 2023; 13(12): 2584-2609. DOI: 10.1158/2159-8290.CD-23-0306..